Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Hereditary cancer | September 30, 2022
Check out a recent publication from Capone et al from the University of Florence!
In this study, the Devyser BRCA test was used to analyze 227 patient DNA samples. They concluded that 100% of the expected SNVS and CNVS were detected and that the single-tube PCR-based library preparation format of the kit offers a decrease in processing time as well as a reduced risk of cross-contamination.
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...
Read More
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
Read More